<DOC>
	<DOCNO>NCT00792831</DOCNO>
	<brief_summary>This open label , un-controlled , phase II , pilot clinical trial test ITF2357 population CLL patient relapse refractory conventional chemotherapy relapse autologus bone marrow transplantation . Patient receive ITF 2357 orally dose 100 mg x 2/die three month subsequent dose modification request patient 's condition . Primary objective : To determine overall response-rate , complete response ( CR ) partial response ( PR ) Secondary objective : To assess safety tolerability ITF2357 ; assess total rate responder ( complete + partial responder ) ; determine 6 month progression free survival ; determine effect drug haematological parameter .</brief_summary>
	<brief_title>Phase II Study Histone-deacetylase Inhibitor ITF2357 Refractory/Relapsed Lymphocytic Leukemia</brief_title>
	<detailed_description>CLL frequent type leukemia western world affect mainly elderly individual , although one third patient le 60 year age diagnosis . CLL heterogeneous disease characterise surprisingly diverse clinical course patient may overall survival time range month decade . CLL account approximately 7000 new case 4500 death per year US . Chemotherapeutic treatment CLL largely ineffective despite new emerge therapy , CLL still remain incurable disease . ITF 2357 novel proprietary molecule synthesize Italfarmaco S.p.A. Research Laboratories , provide establish powerful HDAC-inhibitory activity ( see detail ) . It developend range possible clinical application oncohaematological condition chronic inflammatory disease . The former application consistent well know antitumor pharmacological property HDAC-inhibitors family ( i.e . cell-cycle arrest , pro-apoptotic cell-differentiating effect ) ; latter application ( chronic inflammation ) base demonstrated anticytokine effect ITF 2357 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Givinostat hydrochloride</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Confirmed diagnosis CLL accord NCI Working Group criterion . Male female patient age &gt; 18 ≤75 year Patients relapsed/refractory within 1 month conventional chemotherapy ( &gt; 1 polychemotherapy regimen ) relapse within 3 month autologous bone marrow transplantation ECOG performance score ≤2 Limphocytes ≥10.0x10^9/L platelets &gt; 75.0x10^9/L recovery previous therapy Percentage CD19+/CD5+ leukemic cell &gt; 50 % Adequate cardiac , pulmonary renal function , define LVEF &gt; 45 % , FEV &gt; 50 % creatinine ≤1.5 ULN creatinine clearance ≥50ml/min Serum bilirubine &lt; 1.5xULN , AST ALT &lt; 2.5xULN Serum potassium , phosphorus , total calcium , magnesium &gt; LLN Normal value FT4 TSH ( patient may thyroid hormone replacement ) Negative test betaHCG woman fertile age Documentation write informed consent participate trial Willingness ability comply schedule visit , treatment plan , laboratory test study procedure . Patients Autoimmune haemolytic anaemia , Autoimmune Thrombocytopenic Purpura Fischer Evans Syndrome . Patients autoimmune disease . Patients mark baseline prolongation QTc interval ( e.g . repeat demonstration QTc interval &gt; 450 m ) . Patients history additional risk factor torsade de pointes ( e.g . hearth failure , family history Long QT Syndrome ) The use concomitant medication potential risk torsade de pointes and/or prolong QTc interval Prior treatment HDAC inhibitor . Treatment Rituximab Alemtuzumab within 90 day prior study therapy . Patients HIV positive , patient active EBV , HBV , HCV infection liver cirrhosis Patients active uncontrolled viral bacterial mycotic infection . Major surgery within 4 week study start fully recover previous surgical procedure . Presence medical psychiatric condition may limit full compliance study increase risk associate study participation study drug administration . Patients treatment corticosteroid within 1 month study start Significant cardiovascular disease ( i.e. , uncontrolled arrhythmia , unstable angina ) , major thromboembolic event ( myocardial infarction , stroke , transient ischemic attack , pulmonary embolism , noncatheterrelated deepvein thrombosis ) last 6 month . Uncontrolled hypertension . Malabsorption syndromes . Breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>